| Spectroscopic diagnosis and metabolite characterization of cisplatin resistance regulated by FDFT1 in bladder cancer tissue. | Spectroscopic diagnosis and metabolite characterization of cisplatin resistance regulated by FDFT1 in bladder cancer tissue.
Kanmalar M, Kamal R, Abdul Sani SF, Pathmanathan D, Bm Said NA, Paramanantham Y, Abd Jamil AH, Mun KS, Kuppusamy S, Almugren KS, Almajid HF, Bradley DA. | 06/21/2024 |
| Intramembrane protease SPP defines a cholesterol-regulated abundance control of the mevalonate pathway enzyme squalene synthase. | Intramembrane protease SPP defines a cholesterol-regulated abundance control of the mevalonate pathway enzyme squalene synthase.
Avci D, Heidasch R, Costa M, Lüchtenborg C, Kale D, Brügger B, Lemberg MK., Free PMC Article | 02/28/2024 |
| Squalene synthase predicts poor prognosis in stage I-III colon adenocarcinoma and synergizes squalene epoxidase to promote tumor progression. | Squalene synthase predicts poor prognosis in stage I-III colon adenocarcinoma and synergizes squalene epoxidase to promote tumor progression.
Jiang H, Tang E, Chen Y, Liu H, Zhao Y, Lin M, He L., Free PMC Article | 03/12/2022 |
| Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1. | Ubiquitin specific peptidase 32 acts as an oncogene in epithelial ovarian cancer by deubiquitylating farnesyl-diphosphate farnesyltransferase 1.
Nakae A, Kodama M, Okamoto T, Tokunaga M, Shimura H, Hashimoto K, Sawada K, Kodama T, Copeland NG, Jenkins NA, Kimura T. | 07/3/2021 |
| FDFT1 is a key downstream target of the fasting response and may be involved in CRC cell glucose metabolism. | Fasting inhibits aerobic glycolysis and proliferation in colorectal cancer via the Fdft1-mediated AKT/mTOR/HIF1α pathway suppression.
Weng ML, Chen WK, Chen XY, Lu H, Sun ZR, Yu Q, Sun PF, Xu YJ, Zhu MM, Jiang N, Zhang J, Zhang JP, Song YL, Ma D, Zhang XP, Miao CH., Free PMC Article | 08/13/2020 |
| We have demonstrated the differential relative expression levels of FDFT1 mRNA and protein in various types of cancer based on TMAs and IHC for protein expression, and qPCR analysis for the illustration of mRNA expression. | Characterization of farnesyl diphosphate farnesyl transferase 1 (FDFT1) expression in cancer.
Tüzmen Ş, Hostetter G, Watanabe A, Ekmekçi C, Carrigan PE, Shechter I, Kallioniemi O, Miller LJ, Mousses S. | 01/5/2019 |
| The results indicate that the ennea-peptide CLSPHSMFC, tetra-peptides SMFC, CKTE, and WHQW can effectively inhibit Squalene Synthase activities (IC50 values equal to 64, 76, 87, and 90 muM, respectively) | Discovering Peptide Inhibitors of Human Squalene Synthase Through Screening the Phage-Displayed Cyclic Peptide c7c Library.
Shiuan D, Chen YH, Lin HK, Huang KJ, Tai DF, Chang DK. | 02/4/2017 |
| The minor allele in FDFT1 was associated with advanced fibrosis in the non-steatotic but not in the steatotic subgroup in patients with chronic hepatitis C. | Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C.
Stättermayer AF, Rutter K, Beinhardt S, Wrba F, Scherzer TM, Strasser M, Hofer H, Steindl-Munda P, Trauner M, Ferenci P. | 11/21/2015 |
| Up-regulation of SQS promotes metastasis of lung cancer by enhancing tumor necrosis factor-alpha receptor 1 and nuclear factor-kappaB activation and matrix metallopeptidase 1 expression. | Squalene synthase induces tumor necrosis factor receptor 1 enrichment in lipid rafts to promote lung cancer metastasis.
Yang YF, Jan YH, Liu YP, Yang CJ, Su CY, Chang YC, Lai TC, Chiou J, Tsai HY, Lu J, Shen CN, Shew JY, Lu PJ, Lin YF, Huang MS, Hsiao M. | 11/29/2014 |
| Several critical residues that are involved in binding of NADPH have been identified in the active site of squalene synthase. | Structural insights into the catalytic mechanism of human squalene synthase.
Liu CI, Jeng WY, Chang WJ, Shih MF, Ko TP, Wang AH. | 10/25/2014 |
| HCV infection increases FDFT1 protein level but not FDFT1 mRNA level. | Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation.
Park EM, Nguyen LN, Lim YS, Hwang SB. | 06/28/2014 |
| this finding yields a new method of colorimetric screening for the cellular activity of squalene synthases, which are major targets for cholesterol-lowering drugs. | Construction of carotenoid biosynthetic pathways using squalene synthase.
Furubayashi M, Li L, Katabami A, Saito K, Umeno D. | 03/29/2014 |
| ABHD5, PGRMC1 and SQS are novel markers for sebaceous carcinoma and can reliably distinguish sebaceous neoplasms from non-sebaceous tumors, specifically BCC with clear cell features. | Lipid synthesis and processing proteins ABHD5, PGRMC1 and squalene synthase can serve as novel immunohistochemical markers for sebaceous neoplasms and differentiate sebaceous carcinoma from sebaceoma and basal cell carcinoma with clear cell features.
Chen WS, Chen PL, Li J, Lind AC, Lu D. | 01/18/2014 |
| FDFT1 and its encoded enzyme, squalene synthase, may play an important role in prostate cancer development and its aggressive phenotypes. | Role of squalene synthase in prostate cancer risk and the biological aggressiveness of human prostate cancer.
Fukuma Y, Matsui H, Koike H, Sekine Y, Shechter I, Ohtake N, Nakata S, Ito K, Suzuki K. | 07/13/2013 |
| CTSB and FDFT1 are excluded as candidates for keratolytic winter erythema | Exclusion of CTSB and FDFT1 as positional and functional candidate genes for keratolytic winter erythema (KWE).
Hobbs A, Aron S, Hartshorne S, Hull PR, Ramsay M. | 05/12/2012 |
| NASH is intimately related to fibrosis progression, the FDFT1 SNP is a good candidate for a link with inflammation and fibrosis. | Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity.
Ballestri S, Day CP, Daly AK. | 07/2/2011 |
| In multivariate models adjusted for age, body mass index, diabetes, waist/hip ratios, and levels of glycated hemoglobin, the NAFLD activity score was associated with the SNP rs2645424 on chromosome 8 in farnesyl diphosphate farnesyl transferase 1 (FDFT1) | Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease.
Chalasani N, Guo X, Loomba R, Goodarzi MO, Haritunians T, Kwon S, Cui J, Taylor KD, Wilson L, Cummings OW, Chen YD, Rotter JI, Nonalcoholic Steatohepatitis Clinical Research Network., Free PMC Article | 12/4/2010 |
| Observational study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) | See all PubMed (2) articlesVariation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.
Bailey SD, Xie C, Do R, Montpetit A, Diaz R, Mohan V, Keavney B, Yusuf S, Gerstein HC, Engert JC, Anand S, DREAM investigators. Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
Lipkin SM, Chao EC, Moreno V, Rozek LS, Rennert H, Pinchev M, Dizon D, Rennert G, Kopelovich L, Gruber SB. | 06/30/2010 |
| FDFT1 rs7001819 showed no association with obesity, neither when analysing quantitative traits nor when performing case-control studies of obesity | Studies of CTNNBL1 and FDFT1 variants and measures of obesity: analyses of quantitative traits and case-control studies in 18,014 Danes.
Andreasen CH, Mogensen MS, Borch-Johnsen K, Sandbaek A, Lauritzen T, Almind K, Hansen L, Jørgensen T, Pedersen O, Hansen T, Andreasen CH, Mogensen MS, Borch-Johnsen K, Sandbaek A, Lauritzen T, Almind K, Hansen L, Jørgensen T, Pedersen O, Hansen T., Free PMC Articles: PMC2669074, PMC2669074 | 01/21/2010 |
| Observational study and meta-analysis of gene-disease association. (HuGE Navigator) | Studies of CTNNBL1 and FDFT1 variants and measures of obesity: analyses of quantitative traits and case-control studies in 18,014 Danes.
Andreasen CH, Mogensen MS, Borch-Johnsen K, Sandbaek A, Lauritzen T, Almind K, Hansen L, Jørgensen T, Pedersen O, Hansen T, Andreasen CH, Mogensen MS, Borch-Johnsen K, Sandbaek A, Lauritzen T, Almind K, Hansen L, Jørgensen T, Pedersen O, Hansen T., Free PMC Articles: PMC2669074, PMC2669074 | 03/25/2009 |
| squalene synthase may be involved in the etiology of hypercholesterolemia | Squalene synthase: a critical enzyme in the cholesterol biosynthesis pathway.
Do R, Kiss RS, Gaudet D, Engert JC. | 01/21/2010 |
| the liver X receptor alpha directly silencing the expression of two key cholesterologenic enzymes (lanosterol 14alpha-demethylase (CYP51A1), and squalene synthase (farnesyl diphosphate farnesyl transferase 1)) via novel negative LXR DNA response elements | Regulation of cholesterologenesis by the oxysterol receptor, LXRalpha.
Wang Y, Rogers PM, Su C, Varga G, Stayrook KR, Burris TP., Free PMC Article | 01/21/2010 |
| lysine in codon 45 is conserved across 11 mammals and lies in an exonic splicing enhancer site, suggesting this coding variant in the squalene synthase gene influences plasma cholesterol levels, by affecting the intracellular production of cholesterol | K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.
Do R, Paré G, Montpetit A, Hudson TJ, Gaudet D, Engert JC, Do R, Paré G, Montpetit A, Hudson TJ, Gaudet D, Engert JC. | 01/21/2010 |
| Observational study of gene-disease association. (HuGE Navigator) | See all PubMed (9) articlesCircadian clock gene polymorphisms in alcohol use disorders and alcohol consumption.
Kovanen L, Saarikoski ST, Haukka J, Pirkola S, Aromaa A, Lönnqvist J, Partonen T. CLOCK is suggested to associate with comorbid alcohol use and depressive disorders.
Sjöholm LK, Kovanen L, Saarikoski ST, Schalling M, Lavebratt C, Partonen T. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, Salisbury BA, Ginsburg GS. Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.
Talmud PJ, Drenos F, Shah S, Shah T, Palmen J, Verzilli C, Gaunt TR, Pallas J, Lovering R, Li K, Casas JP, Sofat R, Kumari M, Rodriguez S, Johnson T, Newhouse SJ, Dominiczak A, Samani NJ, Caulfield M, Sever P, Stanton A, Shields DC, Padmanabhan S, Melander O, Hastie C, Delles C, Ebrahim S, Marmot MG, Smith GD, Lawlor DA, Munroe PB, Day IN, Kivimaki M, Whittaker J, Humphries SE, Hingorani AD, ASCOT investigators, NORDIL investigators, BRIGHT Consortium. NPAS2 and PER2 are linked to risk factors of the metabolic syndrome.
Englund A, Kovanen L, Saarikoski ST, Haukka J, Reunanen A, Aromaa A, Lönnqvist J, Partonen T. Multiple genetic variants along candidate pathways influence plasma high-density lipoprotein cholesterol concentrations.
Lu Y, Dollé ME, Imholz S, van 't Slot R, Verschuren WM, Wijmenga C, Feskens EJ, Boer JM. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma.
Skibola CF, Bracci PM, Halperin E, Nieters A, Hubbard A, Paynter RA, Skibola DR, Agana L, Becker N, Tressler P, Forrest MS, Sankararaman S, Conde L, Holly EA, Smith MT. K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.
Do R, Paré G, Montpetit A, Hudson TJ, Gaudet D, Engert JC, Do R, Paré G, Montpetit A, Hudson TJ, Gaudet D, Engert JC. Identification of a chromosome 8p locus for early-onset coronary heart disease in a French Canadian population.
Engert JC, Lemire M, Faith J, Brisson D, Fujiwara TM, Roslin NM, Brewer CG, Montpetit A, Darmond-Zwaig C, Renaud Y, Doré C, Bailey SD, Verner A, Tremblay G, St-Pierre J, Bétard C, Platko J, Rioux JD, Morgan K, Hudson TJ, Gaudet D. | 03/13/2008 |
| in prostate cancer cells SQS expression is enhanced by androgens, channeling intermediates of the mevalonate/isoprenoid pathway toward cholesterol synthesis | Squalene synthase, a determinant of Raft-associated cholesterol and modulator of cancer cell proliferation.
Brusselmans K, Timmermans L, Van de Sande T, Van Veldhoven PP, Guan G, Shechter I, Claessens F, Verhoeven G, Swinnen JV. | 01/21/2010 |